NasdaqGS:ZVRAPharmaceuticals
A Look At Zevra Therapeutics (ZVRA) Valuation After Profitability And MIPLYFFA Commercial Progress
Zevra Therapeutics (ZVRA) is back in focus after reporting better-than-expected Q4 and full-year 2025 earnings, reaching profitability as MIPLYFFA sales, EMA filing plans, and a new GeneDx partnership reshape its rare disease profile.
See our latest analysis for Zevra Therapeutics.
The stock has pulled back, with a 1-day share price decline of 2.16% to US$10.19. However, recent news around MIPLYFFA, EMA progress, the GeneDx partnership and the new CFO hire comes against a 22.3% 90-day share...